ArticleAnimal microbiome2026
A placebo-controlled study of the effects of Saccharomyces cerevisiae var. boulardii CNCM I-1079 probiotic on faecal quality, microbiota and immunity in weaned kittens.
Article in Animal microbiome, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute diarrhoea or soft stools can occur in kittens after environmental challenges. The effects of a probiotic on gastrointestinal and immune biomarkers in kittens exposed to three study events were investigated. Healthy weaned 10-week-old kittens were fed a daily dietary supplement of Saccharomyces cerevisiae var. boulardii CNCM I-1079 (SB-1079) or placebo for 7 weeks (20 kittens/group). The study events were a routine booster vaccination (Week 3), a change in housing (Week 5), and a diet transition (Week 6). Outcomes included faecal scores and percentage dry matter (DM%), total serum IgG, faecal IgA, and faecal microbiota. Statistical analyses included Linear Mixed Models and Generalized Linear Mixed Models with group, time and group × time interaction as fixed effects; longitudinal Kruskal-Wallis test corrected for false discovery rate was used for microbiota outcomes.
resultsFaecal scores were optimal throughout the whole study for 12/20 supplemented kittens vs 8/20 control kittens. Overall, group and group × time did not affect faecal quality or moisture, but in Week 5 (housing change) supplemented kittens had firmer stools (P=0.007) and lower faecal DM% (P=0.032) than placebo kittens. Total serum IgG concentration was affected by group (P=0.028), time (P<0.001) and group × time (P=0.001), and was higher in the probiotic vs placebo group (P<0.039) at Week 7, having increased 250% vs 62% from Week 0. Faecal IgA concentration tended to be higher in the probiotic vs placebo group after booster vaccination (P=0.068). Microbiota composition (weighted Unifrac beta diversity) differed between groups overall (P=0.025), at Week 4 (P=0.017), and in the differences between Week 6 and 7 (P=0.008). In supplemented kittens, relative abundances of Veillonellaceae and Actinobacteria remained stable over the first weeks, and abundance of potential pathogens in the Desulfovibrionaceae family decreased. A decrease in Shannon alpha diversity of faecal microbiota post diet transition was significant in supplemented kittens only (P = 0.008) due to a rapid increase in abundance of the Helicobacteraceae family.
conclusionsThe impacts of SB-1079 on biomarkers of gastrointestinal and immunological health suggest its potential to promote resilience of these systems in young kittens experiencing physiological challenges like new environments and diet transitions. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.